---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting. Topics: Company positioning against complement C5 inhibitors and FcRn blockers, Company target product profile: no Boxed Warning or REMS and self-administered autoinjector, Every-4-week subcutaneous dosing evaluated in the phase 3 trial, Biologic market growth anticipated by the company, and 1 further topic. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

The roles of complement and FcRn inhibitors are being established, especially in patients unresponsive to conventional therapy; Gilhus et al. (2024) recommend them, because of high drug costs, only for difficult-to-treat patients with severe myasthenia gravis not responding to standard immunosuppressive treatment, and as second- or third-line treatment in severe exacerbations and crisis. The company positions claseprubart as a potential first-line biologic intended to displace C5 complement inhibitors and compete with FcRn blockers, and notes that the C5 efficacy data it compares against come from different trials with different designs and populations. Its target profile is a single self-administered 300 mg/2 mL subcutaneous autoinjector dosed every 2 or 4 weeks, without a boxed warning or REMS; the every-4-week arm and a QMG inclusion criterion were added to the phase 3 trial after a post hoc analysis of MaGic. The company proposes that selective inhibition of the classical pathway may lower the risk of infection from encapsulated bacteria by preserving the lectin and alternative pathways.

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/); [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/); [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1); [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial); [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-2.2.2.2-2"></a>

### Company positioning against complement C5 inhibitors and FcRn blockers

> “MaGic Ph. 2 results support a profile with the potential to displace C5 complement inhibitors and compete effectively with FcRns as first-line biologic treatment in growing MG market”
> “Potential for improved efficacy vs. C5 inhibitors with claseprubart may be due to upstream inhibition Upstream inhibition prevents the creation of pro-inflammatory C3a and C3b as well as MAC, potentially providing additional efficacy benefits for AChR+ gMG patients”
> “C5 efficacy data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations.”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-3"></a>

### Company target product profile: no Boxed Warning or REMS and self-administered autoinjector

> “Targeting convenience of a single, self-administered S.C. 300mg/2mL autoinjector dosed every 2 or 4 weeks”
> “NO BOXED WARNING OR REMS RAPID ONSET WITH DURABLE AND CONSISTENT EFFICACY RAPID SELF-ADMINISTERED AUTOINJECTOR CONVENIENCE”
> “Neurologists would start more patients on a complement inhibitor if they do not have a boxed warning or REMS requirement”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-4"></a>

### Every-4-week subcutaneous dosing evaluated in the phase 3 trial

> “Following an initial loading dose, claseprubart 300mg/2mL will be administered every two or four weeks (Q2W or Q4W) via subcutaneous (S.C.) injection.”
> “Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection.”
> “Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways.”

Source: [Dianthus Therapeutics (2026d)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-announces-initiation-phase-3-emerge-trial)

> “This post hoc analysis is driving our decision to add a QMG inclusion criteria and a 300mg/2mL S.C. Q4W arm, in addition to a Q2W arm, in our Phase 3 MG study,”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

<a id="topic-2.2.2.2-5"></a>

### Biologic market growth anticipated by the company

> “gMG biologic market growth driven by the introduction of new treatment options, despite limitations”
> “50% of the gMG market is anticipated to consist of branded biologics, driven by differentiated efficacy, safety and more convenient options”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.2.2.2-6"></a>

### Guideline positioning of complement and FcRn therapies

> “several clinical trials have been published for newer targeted therapies in MG, predominantly those that inhibit the complement and neonatal Fc gamma receptor pathways, the roles of which are being slowly established especially in patients unresponsive to conventional therapy.”

Source: [Jacob et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40940171/)

> “Complement and FcRn inhibitors are recommended as second‐ or third‐line treatment in severe MG exacerbations and crisis.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
